- Home
- CERO vs AWH Comparison
CERO vs AWH Comparison
Compare CERO & AWH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CERO
- AWH
- Stock Information
- Founded
- CERO 2017
- AWH 1993
- Country
- CERO United States
- AWH United States
- Employees
- CERO N/A
- AWH N/A
- Industry
- CERO
- AWH Medical/Dental Instruments
- Sector
- CERO
- AWH Health Care
- Exchange
- CERO Nasdaq
- AWH Nasdaq
- Market Cap
- CERO 12.2M
- AWH 13.5M
- IPO Year
- CERO N/A
- AWH N/A
- Fundamental
- Price
- CERO $0.29
- AWH $0.75
- Analyst Decision
- CERO
- AWH Buy
- Analyst Count
- CERO 0
- AWH 2
- Target Price
- CERO N/A
- AWH $4.40
- AVG Volume (30 Days)
- CERO 174.9M
- AWH 139.7K
- Earning Date
- CERO 11-25-2024
- AWH 11-14-2024
- Dividend Yield
- CERO N/A
- AWH N/A
- EPS Growth
- CERO N/A
- AWH N/A
- EPS
- CERO N/A
- AWH N/A
- Revenue
- CERO N/A
- AWH $8,923,000.00
- Revenue This Year
- CERO N/A
- AWH $15.56
- Revenue Next Year
- CERO N/A
- AWH $105.32
- P/E Ratio
- CERO N/A
- AWH N/A
- Revenue Growth
- CERO N/A
- AWH N/A
- 52 Week Low
- CERO $0.06
- AWH $0.72
- 52 Week High
- CERO $12.80
- AWH $5.65
- Technical
- Relative Strength Index (RSI)
- CERO 73.26
- AWH 33.23
- Support Level
- CERO $0.17
- AWH $0.84
- Resistance Level
- CERO $0.33
- AWH $0.87
- Average True Range (ATR)
- CERO 0.04
- AWH 0.09
- MACD
- CERO 0.02
- AWH -0.02
- Stochastic Oscillator
- CERO 57.68
- AWH 12.87
About CERO CERo Therapeutics Holdings Inc. Common Stock
CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T-cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy.
About AWH Aspira Women's Health Inc.
Aspira Womens Health Inc is engaged in developing and commercializing diagnostic tests for gynecologic diseases. Its products include OvaSuite which is a portfolio of blood tests that applies proprietary algorithms incorporating patient features; OvaWatch intended for use in assessing the risk of ovarian cancer for women with adnexal masses; and Ova1Plus is a portfolio of blood tests, Ova1Plus is a combination of two FDA-cleared tests for women with pelvic masses who are planned for surgery.